Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | 3004299 | PO / MO |
The patient took the second Vivotif dose four days, the third dose eight days, and the fourth dose ten days after the first dose; Case reference number US-BN-2025-001288 is a spontaneous case initially received from a nurse via agency (reference number: USBAV25-1772) on 21-Jul-2025 and concerns an 18-year-old male patient. The patient's medical history and concomitant medication details were not provided. On *07-Jul-2025*, the patient received the first dose of Vivotif (batch number: *3004299 and expiration date: 31-Jul-2026*) orally, *at dose of full capsule*, for typhoid immunization. On *11-Jul-2025, four* days after the first dose, the patient received the second dose of Vivotif (batch number: *3004299 and expiration date: 31-Jul-2026*) orally, *at dose of full capsule* (coded explicitly as 'inappropriate schedule of vaccine administration'). On *15-Jul-2025, eight* days after the second dose, the patient received the third dose of Vivotif (batch number: *3004299 and expiration date: 31-Jul-2026*) orally, *at dose of full capsule* (coded explicitly as 'inappropriate schedule of vaccine administration'). On *17-Jul-2025, ten days* after the third dose, the patient received the fourth dose of Vivotif (batch number: *3004299 and expiration date: 31-Jul-2026*) orally, *at dose of full capsule (coded explicitly as 'inappropriate schedule of vaccine administration').* At the time of *follow-up report, the patient did not experience any adverse event due to Vivotif*. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from a nurse on 29-Sep-2025: New information included suspect product details and confirmation about no adverse event experienced by the patient.; Reporter's Comments: This case concerns an 18-year-old male patient, who received the first dose of Vivotif for an indication of typhoid immunization. As reported, patient received the second dose 4 days later to the first dose; third was 8 days after the second and fourth dose was 10 days after the third dose of Vivotif, which is considered as 'inappropriate schedule of product administered'. Inappropriate schedule of product administered is considered as listed per company convention. At the time of follow-up report, the patient did not experience any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns an 18-year-old male patient, who received the first dose of Vivotif for an indication of typhoid immunization. As reported, patient received the second dose 4 days later to the first dose; third was 8 days after the second and fourth dose was 10 days after the third dose of Vivotif, which is considered as 'inappropriate schedule of product administered'. Inappropriate schedule of product administered is considered as listed per company convention. At the time of follow-up report, the patient did not experience any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Inappropriate schedule of product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None